Zpm-Beta Tablet is a combination pharmaceutical formulation containing Clonazepam 0.5 mg and Propranolol 20 mg, indicated for the management of anxiety disorders, panic attacks, and certain cardiovascular conditions. Clonazepam, a benzodiazepine, exerts its therapeutic effect by enhancing the activity of gamma-aminobutyric acid (GABA) in the central nervous system, producing anxiolytic, anticonvulsant, and muscle relaxant properties. Propranolol, a non-selective beta-adrenergic blocker, reduces heart rate, myocardial contractility, and blood pressure, thereby alleviating symptoms associated with hypertension, arrhythmias, and performance anxiety. The synergistic action of these agents provides both central nervous system calming effects and peripheral cardiovascular stabilization, making Zpm-Beta suitable for patients experiencing anxiety with concomitant tachycardia or hypertension. It is essential to administer this medication under medical supervision, considering potential contraindications such as asthma, bradycardia, and hypersensitivity to either component. Common adverse effects may include dizziness, fatigue, hypotension, and sedation. Dose adjustments are recommended in hepatic or renal impairment. Abrupt discontinuation should be avoided to prevent withdrawal symptoms. Zpm-Beta Tablet should be stored in a cool, dry place away from direct sunlight and out of reach of children. Always consult a healthcare professional before initiating or modifying therapy with Zpm-Beta.